Related Experiment Video
Updated: Apr 16, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis
Marie Leroy1, Guillaume Coiffier1, Charlotte Pronier2
1Service de rhumatologie, hôpital Sud, CHU de Rennes, 16, boulevard de Bulgarie, BP90347, 35203 Rennes cedex 2, France.
Abstract:
Tocilizumab is a humanized antibody against the membrane and soluble receptors for interleukin-6. Tocilizumab is among the disease-modifying antirheumatic drugs (DMARDs) used to treat moderate-to-severe active rheumatoid arthritis (RA) refractory to conventional DMARDs. We report a case of macrophage activation syndrome that complicated acute hepatitis E and started within 24hours after the fourth tocilizumab infusion in a patient with RA.
More Related Videos
10:35Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Related Concept Videos
Hypersensitivity Reactions: Cytolytic Reactions
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Hypersensitivity Reactions: Immune-Complex Reactions
Hepatitis
Rheumatic Heart Disease I: Introduction